Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
European Medicines Agency
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Novel MS Drug Offers Good Functional Outcomes
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Drug Safety Labeling Changes
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Study hints of rituximab MS benefit
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.

Pages